Anti CD7 CAR-T cells therapy (Peking University People'S Hospital)

N/A

Report date: 2025/08/29 20:01:31

Base Information

Drug NameAnti CD7 CAR-T cells therapy (Peking University People'S Hospital)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT-cell antigen CD7 inhibitorsT lymphocyte replacements
TargetsT-cell antigen CD7
Therapy Area/IndicationsLymphoma, T-Cell, PeripheralPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesPeking University People'S Hospital
China Registration ClassN/A

Develop Information

Active CompaniesPeking University People'S Hospital
Inactive CompaniesN/A
Active IndicationsLymphoma, T-Cell, PeripheralPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A